Stock Research for LLY

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

LLY Stock Chart & Research Data

The LLY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the LLY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


LLY Due diligence Resources & Stock Charts

The LLY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View LLY Detailed Price Forecast - CNN Money CNN View LLY Detailed Summary - Google Finance
Yahoo View LLY Detailed Summary - Yahoo! Finance Zacks View LLY Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View LLY Trends & Analysis - Trade-Ideas Barrons View LLY Major Holders - Barrons
NASDAQ View LLY Call Transcripts - NASDAQ Seeking View LLY Breaking News & Analysis - Seeking Alpha
Spotlight View LLY Annual Report - CompanySpotlight.com OTC Report View LLY OTC Short Report - OTCShortReport.com
TradeKing View LLY Fundamentals - TradeKing Charts View LLY SEC Filings - Bar Chart
WSJ View Historical Prices for LLY - The WSJ Morningstar View Performance/Total Return for LLY - Morningstar
MarketWatch View the Analyst Estimates for LLY - MarketWatch CNBC View the Earnings History for LLY - CNBC
StockMarketWatch View the LLY Earnings - StockMarketWatch MacroAxis View LLY Buy or Sell Recommendations - MacroAxis
Bullish View the LLY Bullish Patterns - American Bulls Short Pains View LLY Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View LLY Stock Mentions - StockTwits PennyStocks View LLY Stock Mentions - PennyStockTweets
Twitter View LLY Stock Mentions - Twitter Invest Hub View LLY Investment Forum News - Investor Hub
Yahoo View LLY Stock Mentions - Yahoo! Message Board Seeking Alpha View LLY Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for LLY - SECform4.com Insider Cow View Insider Transactions for LLY - Insider Cow
CNBC View LLY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for LLY - OTC Markets
Yahoo View Insider Transactions for LLY - Yahoo! Finance NASDAQ View Institutional Holdings for LLY - NASDAQ


Stock Charts

FinViz View LLY Stock Insight & Charts - FinViz.com StockCharts View LLY Investment Charts - StockCharts.com
BarChart View LLY Stock Overview & Charts - BarChart Trading View View LLY User Generated Charts - Trading View




Latest Financial News for LLY


Pacira's Study on Exparel Label Expansion Meets Endpoints
Posted on Thursday January 17, 2019

Pacira's (PCRX) phase IV study of its lead drug Exparel in patients undergoing Cesarean section achieves primary endpoint.


Lilly's 10-Day Sprint For Loxo Could Put Other Names On The Table
Posted on Thursday January 17, 2019

Pharma giant Eli Lilly put together its winning bid for Loxo Oncology in just 10 days ahead of the J.P. Morgan Healthcare Conference, according to documents filed Thursday with the SEC.


Ligand (LGND) Takes a Hit on Citron's Negative Research Report
Posted on Thursday January 17, 2019

Ligand (LGND) plunges as short-seller Citron Research questions the company's business prospects.


Citron Says Ligand Has 80% Downside in Explosive Note
Posted on Thursday January 17, 2019

Citron Research, the activist short-seller headed by Andrew Left, has dug up some nasty evidence against Ligand Pharmaceuticals Inc. (LGND). In a 23-page report, Citron accused the San Diego-based biopharmaceutical company of misleading investors, adding that its future revenue calculations are a "pipe dream." The short seller then slapped a $35 price target on the stock, implying 80% downside from the report’s publication date. After failing to successfully develop its own drugs, Ligand switched its business model to focus on collecting royalties and milestone payments from compounds and intellectual property that it licenses to other drug developers.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.